Eli Lilly and Company (LLY) — closed signal from May 23, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on August 21, 2026.
Predicted vs. what happened
What happened
Reached its target in 34 days.
The thesis — published May 23, 2026
Eli Lilly looks like a strong growth company because demand for its obesity treatments is clearly visible and new late-stage results for retatrutide reinforce its leadership. Profitability and margins are unusually strong for a large drugmaker, and recent news keeps attention on next-generation metabolic medicines. The shares have run up, so buying on pullbacks is viewed as a cleaner way to enter ahead of the main obesity catalyst.
Primary drivers
- Retatrutide trial news bolsters Lillys next-gen obesity drugs
- Visible sales demand across obesity and diabetes products
- Reliable earnings and margins support higher valuation
- Lower sensitivity to market swings helps reduce short-term noise
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.